Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Devgen NV

Latest From Devgen NV

Bone Therapeutics names new CFO

Wim Geomaere


Start-Up Quarterly Statistics, Q3 2011

Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.

BioPharmaceutical Medical Device

ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem

Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is working on a medicinal chemistry "trick" to enable it to develop drugs which inhibit Rho Kinase (ROCK) without causing the unwanted side-effects that have tended to interfere with the development of such compounds.

Gastrointestinal Dermatology

Biocartis hires Hilde Windels as CFO

Biocartis, a developer of molecular diagnostic solutions, has appointed Hilde Windels chief financial officer, as well as managing director of Biocartis NV (a wholly owned subsidiary of Biocartis SA) and director of Biocartis BV (the Dutch subsidiary). Ms Windels is currently on the board of MDX Health and Flanders Bio, and was previously CFO of Devgen.

See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Devgen NV
  • Senior Management
  • Thierry Bogaert, PhD, CEO
    Wim Goemaere, CFO
  • Contact Info
  • Devgen NV
    Phone: (32) 9 324 24 24
    Technologiepark 30
    Ghent - Zwijnaarde, B-9052